All In Biotech

Drug Trial Radar · NCT07047365

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Evaluating TQB2930 Combined With Investigator's Choice of Chemotherapy Versus Trastuzumab Combined With Investigator's Choice of Chemotherapy in the Treatment of HER2-Positive Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 416 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

416

Planned (sponsor's estimate)

Start

Jul 25, 2025

Primary completion

Jun 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Jul 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.

Conditions

  • HER2-positive Advanced Breast Cancer

Interventions

  • TQB2930+ chemotherapyDrug

    TQB2930 injection is a HER2 bispecific antibody drug; Chemotherapy: Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.

  • Trastuzumab+ chemotherapyDrug

    Trastuzumab is a HER2-specific targeted drug; Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection and Eribulin Mesylate Injection are Chemotherapy Drugs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Baseline up to IRC-assessed Disease Progression(PD), approximately 1 years

Locations

75 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Not yet recruiting

  • Anhui Provincial Hospital( The First Affiliated Hospital of USTC)

    Hefei, Anhui, China · Not yet recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • The Fifth Medical Center of Chinese People's Liberation Army General Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Chong Qing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Fuzhou First Generel Hospital Affiliated with Fujian Medical University

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Cancer Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Sun Yat - sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Not yet recruiting

  • The Second Affiliated Hospital of Guangxi University of Science and Technology

    Liuzhou, Guangxi, China · Not yet recruiting

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China · Not yet recruiting

  • Affiliated Cancer Hospital of Guangxi Medical Universit

    Nanning, Guangxi, China · Not yet recruiting

  • The Affiiated Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China · Not yet recruiting

  • Hainan General Hospital

    Haikou, Hainan, China · Not yet recruiting

  • The First Hospital of Qinhuangdao

    Qinhuangdao, Hebei, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Tangshan People's Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • The First Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • Jiamusi Tuberculosis Hospital (Jiamusi Tumor Hospital)

    Jiamusi, Heilongjiang, China · Not yet recruiting

  • Mudanjiang Cancer Hospital

    Mudanjiang, Heilongjiang, China · Not yet recruiting

  • AnYang Tumor Hospital

    Anyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China · Not yet recruiting

  • Nanyang Second General Hospital

    Nanyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Jingmen People's Hospital

    Jingmen, Hubei, China · Not yet recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Not yet recruiting

  • The First People's Hospital of Changde City

    Changde, Hunan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • People's Hospital of Hunan Province

    Changsha, Hunan, China · Not yet recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • The Central Hospital of Yongzhou

    Yongzhou, Hunan, China · Not yet recruiting

  • Zhangjiajie People's Hospital

    Zhangjiajie, Hunan, China · Not yet recruiting

  • JiangSu Cancer Hosipital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The Affiliated Sir Run Run Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.